<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436800</url>
  </required_header>
  <id_info>
    <org_study_id>L_9281</org_study_id>
    <nct_id>NCT00436800</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in&#xD;
      the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To assess the toxicity, duration of response, time to progression, progression-free survival,&#xD;
      overall survival and cancer-related symptoms in the first line treatment of patients with&#xD;
      metastatic or recurrent NPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Tumor response rate based on Response Evaluation Criteria in Solid Tumour (RECIST) criteria</measure>
    <time_frame>Baseline to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Clinical and laboratory criteria</measure>
    <time_frame>Baseline to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0</measure>
    <time_frame>Baseline to 30 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAE)</measure>
    <time_frame>Baseline to 30 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop-out rate</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms.</measure>
    <time_frame>Baseline to end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/m² over 10mg/m²/min</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>100 mg/m² over 2 hours.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically proven nasopharyngeal carcinoma (NPC)&#xD;
             with metastatic or recurrent disease that is not amenable to potentially curative&#xD;
             surgery or radiotherapy. They must not have prior chemotherapy for the treatment of&#xD;
             metastatic or recurrent disease.&#xD;
&#xD;
          -  Prior neoadjuvant, adjuvant or concurrent chemotherapy is allowed as long as a minimum&#xD;
             period of 6 weeks has elapsed since the last day of treatment. This includes the use&#xD;
             of carboplatin or cisplatin.&#xD;
&#xD;
          -  Patients must have at least one uni-dimensional measurable lesion (according to RECIST&#xD;
             criteria)&#xD;
&#xD;
          -  Prior RT or surgery to the target lesion(s) is allowed as long as there is documented&#xD;
             disease progression within the RT/ surgical field, and a minimum period of 6 weeks has&#xD;
             elapsed since the last day of treatment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0-2&#xD;
&#xD;
          -  No serious, uncontrolled medical conditions that may be aggravated by treatment.&#xD;
&#xD;
          -  No other malignancy(s), except completely excised basal or squamous cell carcinoma of&#xD;
             the skin, or completely treated carcinoma-in-situ of the cervix.&#xD;
&#xD;
          -  Adequate hematological function:absolute granulocyte count &gt; 1.5 x 10^9/L, platelet&#xD;
             count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Adequate renal and hepatic functions:·serum creatinine &lt; 1.25 x upper normal limit&#xD;
             (UNL) or a calculated creatinine clearance &gt; 50 mL/min·serum bilirubin &lt; 2 x UNL and&#xD;
             Aspartate aminotransferase/Alanine aminotransferase &lt; 3 x UNL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Oxaliplatin or Gemcitabine.&#xD;
&#xD;
          -  Patients who have persistent grade 2 or more sensory and/or motor neuropathy, or&#xD;
             ototoxicity resulting from prior cisplatin/ carboplatin.&#xD;
&#xD;
          -  Active or past history of central nervous system metastasis from the primary tumor&#xD;
&#xD;
          -  Potentially life-threatening infections&#xD;
&#xD;
          -  Patients have used any investigational drug treatment in the month prior to inclusion.&#xD;
&#xD;
          -  Pregnancy or not exercising appropriate birth control during the course of the study.&#xD;
             Breast-feeding women&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Chan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

